CABA Cabaletta Bio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CABA

Price (delayed)

$16.02

Market cap

$686.45M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.71

Enterprise value

$575.22M

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, ...

Highlights
CABA's EPS is up by 3.9% YoY
The equity has soared by 87% YoY but it has contracted by 8% from the previous quarter
Cabaletta Bio's quick ratio has decreased by 25% QoQ but it has increased by 4.6% YoY
CABA's net income is down by 22% year-on-year and by 9% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cabalettabio.com
Peers: OMGA

Key stats

What are the main financial stats of CABA
Market
Shares outstanding
42.85M
Market cap
$686.45M
Enterprise value
$575.22M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.96
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$62.48M
EBITDA
-$57.12M
Free cash flow
-$50.05M
Per share
EPS
-$1.71
Free cash flow per share
-$1.26
Book value per share
$4.04
Revenue per share
$0
TBVPS
$4.35
Balance sheet
Total assets
$173.29M
Total liabilities
$12.36M
Debt
$4.27M
Equity
$160.92M
Working capital
$155.56M
Liquidity
Debt to equity
0.03
Current ratio
15.65
Quick ratio
15.49
Net debt/EBITDA
1.95
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-43.2%
Return on equity
-47%
Return on invested capital
-178.9%
Return on capital employed
-38.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CABA stock price

How has the Cabaletta Bio stock price performed over time
Intraday
-0.19%
1 week
-14.19%
1 month
8.61%
1 year
242.31%
YTD
73.19%
QTD
5.26%

Financial performance

How have Cabaletta Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$67.82M
Net income
-$62.48M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 31% YoY and by 11% from the previous quarter
CABA's net income is down by 22% year-on-year and by 9% since the previous quarter

Growth

What is Cabaletta Bio's growth rate over time

Valuation

What is Cabaletta Bio stock price valuation
P/E
N/A
P/B
3.96
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CABA's EPS is up by 3.9% YoY
CABA's price to book (P/B) is 98% higher than its 5-year quarterly average of 2.0 and 37% higher than its last 4 quarters average of 2.9
The equity has soared by 87% YoY but it has contracted by 8% from the previous quarter

Efficiency

How efficient is Cabaletta Bio business performance
The ROIC has grown by 12% from the previous quarter
Cabaletta Bio's return on assets has increased by 8% YoY and by 7% QoQ
Cabaletta Bio's ROE has increased by 7% from the previous quarter and by 7% YoY

Dividends

What is CABA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CABA.

Financial health

How did Cabaletta Bio financials performed over time
Cabaletta Bio's total liabilities has soared by 113% YoY and by 18% from the previous quarter
Cabaletta Bio's total assets has soared by 89% YoY but it has decreased by 6% from the previous quarter
CABA's debt is 97% smaller than its equity
The equity has soared by 87% YoY but it has contracted by 8% from the previous quarter
Cabaletta Bio's debt to equity has soared by 50% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.